Manesh Vara Email & Phone Number

London, England, United Kingdom

• Part of the special care business unit, accountable for the cystic fibrosis (CF) portfolio• Engagement with key CF consultants, specialist nurses, physiotherapists and pharmacists to optimise brands usage and patient care.• Accounts segmentation and prioritisation with development of business plans to enhance CF portfolio awareness and support improved customer experience.

North Central London

• Accountable for the Cardiovascular Business in North Central London, working with hospital consultants, clinical nurse specialists (anticoagulation) and pharmacists.• Successful collaboration with a North London Trust to reduce local health inequalities by improving access to anticoagulation services and optimising treatment for domiciliary patients, providing access to 361 patients for anticoagulation in North Central London.• Improving patient access for new lipid lowering therapy by formulary inclusion at all lipid centres in North Central London within 3 months of launch and achieving territory performance of 46% growth (Apr-Jun22 vs Jan-Mar22) against London region of 25% and National of 36%, same period.• Overachieving sales growth in a well established DOAC market with well-grounded competitor; territory growth of 12% (Apr-Jun22 vs Jan-Mar22) against London region of 8% and National of 10%, same period.

North Central London

• Part of the Cardiovascular Business Unit within AstraZeneca managing key Hospital Accounts. • Working with Payors, Hospital Consultants, Pharmacists & Specialist Cardiac Nurses to manage process, pathway and protocols from implementation to full usage of product.• Development of sound account plans to achieve targets and support development and mobilisation of brand advocates regionally and nationally. • Interpretation of data via Spotfire data visualisation and analytics software and translation of this into planning activities.• Territory currently experiencing 15% growth rate for (Jan – Oct) 2017 vs. same period 2016; against London growth of 13%.• 110% target at last full half year H2 2017.• Achieved protocol inclusion for new licensed indication (Sept 2017), opening up access to a further 271 patients in North Central London.• Gained formulary / ACS protocol expansion into all ACS (April 2016); this provides access to a further 210 patients in London.• Within top 5 of accelerated cash growth challenge Sept. – Dec 2016 out of 49 account managers.

North Central & East London

• Delivering brand value proposition into key strategic accounts to improve local outcomes.• Analysing QOF data together with local account data to target key accounts and influence change.• Key account management of important customers and area, in Primary & Secondary care.• Working with health economics team to develop business 2 business analytical tool.• Tertiary centre 60% cash growth Q3 2014 vs. same period Q3 2013.• Priority account cash sales growth 1-2% (Q3 2014 vs. Q3 2013) against London growth of -2% same period.. • Delivered 103% of target 2014.

East London

North, East London, Greenwich & Hampshire